ERJ Open Res 2017; 3: 00002-2017
5 May 2021
This Information Note is intended to assist national TB programmes and health personnel worldwide to maintain essential tuberculosis (TB) services during the COVID-19 pandemic and in the recovery phase. It is important that recent progress made in TB prevention and care is not reversed b...y COVID-19. The WHO Global TB Programme, along with WHO regional and country offices, developed this note in response to questions received from Member States and other partners since the start of the pandemic. The note includes references to other published WHO information products relevant to TB practitioners. WHO continues to monitor the situation closely for any changes that may influence this note and will issue updates should any factors change.
more
Manual for Trainers and Programme Managers
MMWR. Recommendations and Reports:
December 16, 2005 / 54(RR15);49-55
Toolkit
HIV Treatment and Care
Please download the other parts from the Webseite
Blueprint for EECA countries, first edition
МОДЕЛЬ ПРОТИВОТУБЕРКУЛЕЗНОЙ ПОМОЩИ, ОРИЕНТИРОВАННАЯ НА НУЖДЫ ЛЮДЕЙ
Концептуальный проект модели для стран Восточной Европы и Центрально...й Азии, первое издание
more
The handbook on supply chain management for HIV/AIDS commodities was written to assist program managers to plan and implement day–to-day management of all drugs and medical supplies for an HIV/AIDS program. Many of the suggested techniques described in this handbook are helpfu...l to program managers starting to plan or scale-up provision of drugs and supplies for a HIV/AIDS program. Additionally, some of the information may be helpful to readers who are implementing a new program and may not have robust logistics systems in place. For other readers, this handbook may serve as a checklist of systems and procedures that need to be in place in order to manage the many of the health commodities required for the HIV/AIDS program.
more
The first important change is a new priority ranking of the available medicines for MDR-TB treatment, based on a careful balance between expected benefits and harms. Treatment success for MDR-TB is currently low in many countries. This could be increased by improving access to the highest-ranked med...icines for all patients with MDR-TB.
more